- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- RPh201 Cohort A, Placebo Cohort A, RPh201 Cohort B, Placebo Cohort B
- Drug · Other
- Lead sponsor
- Regenera Pharma Ltd
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 15
- States / cities
- Palo Alto, California • Pasadena, California • Orange, Connecticut + 12 more
- Conditions
- Non Arteritic Anterior Ischemic Optic Neuropathy
- Interventions
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure
- Drug · Other
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 44
- States / cities
- Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more
- Conditions
- Nonarteritic Anterior Ischemic Optic Neuropathy
- Interventions
- PDE5 Inhibitors
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Altos, California • National City, California + 40 more
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
- Interventions
- Arm 1
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Non Arteritic Ischemic Optic Neuropathy
- Interventions
- dalfampridine, Placebo
- Drug
- Lead sponsor
- Neuro-Ophthalmologic Associates, PC
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania